Free Trial
NASDAQ:KOD

Kodiak Sciences Q1 2024 Earnings Report

Kodiak Sciences logo
$4.44 +0.54 (+13.85%)
Closing price 04:00 PM Eastern
Extended Trading
$4.47 +0.03 (+0.79%)
As of 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kodiak Sciences EPS Results

Actual EPS
-$0.82
Consensus EPS
-$1.09
Beat/Miss
Beat by +$0.27
One Year Ago EPS
N/A

Kodiak Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kodiak Sciences Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Wednesday, May 15, 2024
Conference Call Time
4:15PM ET

Upcoming Earnings

Kodiak Sciences' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Thursday, August 14, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Kodiak Sciences Earnings Headlines

Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
See More Kodiak Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kodiak Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kodiak Sciences and other key companies, straight to your email.

About Kodiak Sciences

Kodiak Sciences (NASDAQ:KOD), Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for retinal diseases. Headquartered in Palo Alto, California, Kodiak leverages proprietary antibody biopolymer conjugate (ABC) technology to create targeted treatments that aim to improve durability, durability and efficacy in the eye. The company was founded in 2009 and has steadily advanced a pipeline of product candidates designed to address unmet needs in chronic ophthalmic conditions.

The company’s lead candidate, KSI-301, is an anti-VEGF antibody biopolymer conjugate that is being evaluated in pivotal Phase 3 studies for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). By combining a high-molecular-weight polymer with an anti-VEGF antibody, KSI-301 is engineered to extend treatment intervals and potentially reduce the frequency of intravitreal injections for patients. Kodiak has also initiated early-stage programs exploring novel targets in retinal vascular disease and inherited retinal disorders.

Kodiak Sciences operates research and development facilities in both the United States and Europe, enabling global collaboration and clinical trial execution across multiple geographies. The company has established strategic partnerships with academic institutions and contract research organizations to support its translational efforts. Kodiak’s international reach is further strengthened by regulatory interactions in key markets, positioning the company to seek approvals and commercial launches in North America, Europe and select Asia-Pacific territories.

Leadership at Kodiak Sciences includes President and Chief Executive Officer Victor Perlroth, who brings extensive experience in ophthalmology drug development, and Chief Medical Officer Manjula Mahajan, M.D., a recognized expert in retinal disease clinical research. The management team and board combine scientific, clinical and commercial expertise to drive the advancement of Kodiak’s pipeline. As Kodiak continues its late-stage programs, the company remains committed to delivering transformative therapies for patients suffering from vision-threatening conditions.

View Kodiak Sciences Profile

More Earnings Resources from MarketBeat